Intravenous-Pegloticase-Market-Challenges-and-Opportunities
Intravenous pegloticase is an advanced biologic therapy specifically designed for the treatment of chronic, refractory gout, which is a severe form of gout that does not respond adequately to standard urate-lowering therapies. Gout is characterized by persistently elevated levels of uric acid in the blood, resulting in the formation of monosodium urate crystals that can accumulate in joints and soft tissues. This accumulation can lead to recurrent flare-ups, joint damage, the formation of tophi, and a significant decline in the quality of life for affected individuals.